A5054180083- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Psychosomatic Disorders and Their Treatments
- Long-Term Effects of COVID-19
- Neurological Disorders and Treatments
- Suicide and Self-Harm Studies
- Neuroscience and Neuropharmacology Research
- COVID-19 and Mental Health
- Neurological Disease Mechanisms and Treatments
- Acute Ischemic Stroke Management
- Functional Brain Connectivity Studies
- Bipolar Disorder and Treatment
- EEG and Brain-Computer Interfaces
- COVID-19 Clinical Research Studies
- Intensive Care Unit Cognitive Disorders
- Stress Responses and Cortisol
- Attention Deficit Hyperactivity Disorder
- Tryptophan and brain disorders
- Neurological disorders and treatments
- Extracellular vesicles in disease
- Parkinson's Disease Mechanisms and Treatments
- Stroke Rehabilitation and Recovery
- Mental Health and Psychiatry
- Nerve injury and regeneration
- Neurology and Historical Studies
Moscow Research and Clinical Center for Neuropsychiatry
2016-2025
Pirogov Russian National Research Medical University
2016-2025
University College London
2024
National Cerebral and Cardiovascular Center
2024
Yale University
2024
Kyoto University
2024
Ministry of Health of the Russian Federation
2019-2024
National Hospital for Neurology and Neurosurgery
2024
Institute of Practical Psychology and Psychoanalysis
2015-2023
Moscow City Clinical Hospital after V.M. Buyanov
2023
Two previous pan-European consensus meetings, the 1995 and 2006 Helsingborg were convened to review scientific evidence state of current services identify priorities for research development set targets stroke care decade follow. Adhering same format, European Stroke Organisation (ESO) prepared a Action Plan (ESAP) years 2018 2030, in cooperation with Alliance Europe (SAFE). The ESAP included seven domains: primary prevention, organisation services, management acute stroke, secondary...
The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with and potential risk factors.
A substantial portion of people with COVID-19 subsequently experience lasting symptoms including fatigue, shortness breath, and neurological complaints such as cognitive dysfunction many months after acute infection. Emerging evidence suggests that this condition, commonly referred to long COVID but also known post-acute sequelae SARS-CoV-2 infection (PASC) or post-COVID-19 could become a significant global health burden.While the number studies investigating condition is increasing, there...
To identify the rates of neurological events following administration mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in U.S..
Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed absence an agreed definition. We investigated post-COVID-19 condition (PCC) (WHO definition), at 6- 12-months follow-up, amongst previously hospitalised assessed risk factors.Prospective cohort study with confirmed Moscow, between April August, 2020. Two follow-up telephone interviews, using International Severe Acute Respiratory Emerging Infection Consortium survey, 6 12 months after...
Abstract The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges gaps in provision of care services for people with epilepsy other neurological disorders ensure a comprehensive, coordinated response across sectors burden neurologic diseases promote brain health life-course. Headache constitute second most burdensome all after stroke, but first if young midlife adults are taken...
Poststroke epilepsy (PSE) is associated with higher mortality and poor functional cognitive outcomes in patients stroke. With the remarkable development of acute stroke treatment, there a growing number survivors PSE. Although approximately 10% develop PSE, given significant burden worldwide, PSE problem survivors. Therefore, attention health policymakers funding are required to promote prevention research. The current definition includes unprovoked seizures occurring more than 7 days after...
The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with a placebo.This study prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated (30 mL/d) or placebo (saline) once daily for 21 days, beginning 24 72 hours after onset. also participated standardized rehabilitation program days that initiated within primary end point...
No drug treatment to date has shown convincing clinical evidence of restoring cognitive function or preventing further decline after stroke. The ongoing ARTEMIDA study will evaluate the efficacy and safety Actovegin for symptomatic post-stroke impairment (PSCI) explore whether any disease-modifying effect by assessing changes are sustained treatment.ARTEMIDA is a 12-month, multicentre trial in patients (planned total 500, now recruited) with following ischaemic consists baseline screening...
Vascular cognitive impairment (VCI) is a complex spectrum encompassing post-stroke (PSCI) and small vessel disease-related impairment. Despite the growing health, social, economic burden of VCI, to date, no specific treatment available, prompting introduction concept disease modifier. Within this clinical spectrum, VCI PSCI remain advancing conditions as neurodegenerative diseases with progression both vascular degenerative lesions accounting for decline. Disease-modifying strategies should...
Summary Objective In 2014 the European Union–funded E‐ PILEPSY project was launched to improve awareness of, and accessibility to, epilepsy surgery across Europe. We aimed investigate current use of neuroimaging, electromagnetic source localization, imaging postprocessing procedures in participating centers. Methods A survey on clinical imaging, methods candidates distributed among 25 centers consortium. descriptive analysis performed, results were compared existing guidelines...
We explored the current practice with respect to neuropsychological assessment of surgical epilepsy patients in European centers, aim harmonizing and establishing common standards. Twenty-six centers members "E-PILEPSY" (a pilot network reference refractory surgery), were asked report status adults children via two different surveys. There was a consensus among these regarding role neuropsychology presurgical workup. Strong agreement found on indications (localization, epileptic...
The coronavirus disease 2019 (COVID-19) pandemic has affected the care of all patients around world. International League Against Epilepsy (ILAE) COVID-19 and Telemedicine Task Forces examined, through surveys to people with epilepsy (PWE), caregivers, health professionals, how well-being, care, services for PWE. ILAE included a link on their website whereby PWE and/or caregivers could fill out survey (in 11 languages) about impact pandemic, including access mental health, 6-item Kessler...
Abstract Background An online 3-item survey was sent to the European Academy of Neurology (EAN) community and inquired about persistence SARS-CoV-2 vaccination skepticism underlying thoughts factors restricting vaccine use among patients with neurological conditions. Results We obtained 616 responses from 84 countries, predominantly Europe. In view treating neurologist, multiple sclerosis (MS), neuroimmunological disorders (ND), chronic infections continued have high levels toward...
The Commission of European Affairs the International League Against Epilepsy published `Appropriate Standards for Care Across Europe' which contained recommendations use electroencephalography (EEG) in diagnosis epilepsy (Brodie et al. Epilepsia 1997; 38:1245). need a more specific basic document EEG methodology was recognized and Subcommission on asked to produce detailed guidelines be used across Europe recognizing range practices laboratories. There are many general but this focuses...